1038588-24-7

Usage

Uses

Since the provided materials do not explicitly state the uses or potential applications of 2,4-dichloro-7H-Pyrrolo[2,3-d]pyrimidine-7-carboxylic acid 1,1-dimethylethyl ester, its applications can only be inferred based on its chemical structure and properties. Here are some possible uses in different industries:
Used in Pharmaceutical Industry:
2,4-dichloro-7H-Pyrrolo[2,3-d]pyrimidine-7-carboxylic acid 1,1-dimethylethyl ester could be used as a chemical intermediate for the synthesis of pharmaceutical compounds, given its unique pyrrolopyrimidine core and functional groups. 2,4-dichloro-7H-Pyrrolo[2,3-d]pyriMidine-7-carboxylic acid 1,1-diMethylethyl ester may serve as a building block for the development of new drugs with potential therapeutic applications.
Used in Chemical Research:
In the field of chemical research, 2,4-dichloro-7H-Pyrrolo[2,3-d]pyrimidine-7-carboxylic acid 1,1-dimethylethyl ester may be utilized as a starting material or a reagent in various organic synthesis reactions. Its unique structure and functional groups could be explored for the development of novel chemical reactions and methodologies.
Used in Material Science:
2,4-dichloro-7H-Pyrrolo[2,3-d]pyriMidine-7-carboxylic acid 1,1-diMethylethyl ester's specific functional groups and molecular structure may also find applications in material science, where it could be used as a component in the development of new materials with unique properties. For example, it may be incorporated into polymers, coatings, or other materials to impart specific characteristics, such as improved stability, reactivity, or selectivity.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 90213-66-4 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 1236078-22-0 C₄₇H₃₅N₅O₂ 
• 1236078-21-9 tert-butyl 2,4-di(biphenyl-3-yl)-7H-pyrrolo[2,3-d]pyrimidine-7-carboxylate 
• 1236078-20-8 C₂₅H₂₅N₃O₄ 
• 1236078-19-5 C₃₁H₃₇N₃O₂ 
• 1236078-18-4 tert-butyl 2,4-diphenyl-7H-pyrrolo[2,3-d]pyrimidine-7-carboxylate 
• 1393648-54-8 tert-butyl 2-chloropyrrolo[2,3-d]pyrimidine-7-carboxylate 
• 909562-68-1 2-chloro-7-(3,5-difluorobenzyl)-7H-pyrrolo[2,3-d]-pyrimidine 
• 1194537-67-1 tert-butyl 4-(4-{[7-(3,5-difluorobenzyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}phenyl)piperazine-1-carboxylate 
• 909564-40-5 7-(3,5-difluorobenzyl)-N-(4-piperazin-1-ylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
• 909561-13-3 ethyl [4-(4-{[7-(3,5-difluorobenzyl)-7H-pyrrolo[2,3-d]-pyrimidin-2-yl]amino}phenyl)piperazin-1-yl]acetate 
• 909561-14-4 [4-(4-{[7-(3,5-difluorobenzyl)-7H-pyrrolo[2,3-d]-pyrimidin-2-yl]amino}phenyl)piperazin-1-yl]acetic acid 
• 1792180-81-4 (-) 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one 

Relevant academic research and scientific papers

Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer

New targeted therapy approaches for certain subtypes of breast cancer, such as triple-negative breast cancers and other aggressive phenotypes, are desired. High levels of the mitotic checkpoint kinase Mps1/TTK have correlated with high histologic grade in breast cancer, suggesting a potential new therapeutic target for aggressive breast cancers (BC). Novel small molecules targeting Mps1 were designed by computer assisted docking analyses, and several candidate compounds were synthesized. These compounds were evaluated in anti-proliferative assays of a panel of 15 breast cancer cell lines and further examined for their ability to inhibit a variety of Mps1-dependent biological functions. The results indicate that the lead compounds have strong anti-proliferative potential through Mps1/TTK inhibition in both basal and luminal BC cell lines, exhibiting IC50values ranging from 0.05 to 1.0?μM. In addition, the lead compounds 1 and 13 inhibit Mps1 kinase enzymatic activity with IC50values from 0.356?μM to 0.809?μM, and inhibited Mps1-associated cellular functions such as centrosome duplication and the spindle checkpoint in triple negative breast cancer cells. The most promising analog, compound 13, significantly decreased tumor growth in nude mice containing Cal-51 triple negative breast cancer cell xenografts. Using drug discovery technologies, computational modeling, medicinal chemistry, cell culture and in vivo assays, novel small molecule Mps1/TTK inhibitors have been identified as potential targeted therapies for breast cancers.

2,6-DICHLORO-8-IODO-7-DEAZAPURINE FOR SYNTHESIZING POLYSUBSTITUTED 7-DEAZAPURINE DERIVATIVE

PROBLEM TO BE SOLVED: To overcome many times and labors needed for synthesizing various polysubstituted 7-deazapurine derivatives which is expected usefulness or the like as pharmaceutical because they are conventionally synthesized through several synthetic routes depending on kinds and positions of substituents. SOLUTION: Used is 2,6-dichloro-8-iodo-7-deazapurine represented by the following formula (1) available as a key intermediate of polysubstituted 7-deazapurine derivatives. Predetermined substituents can be introduced to 8-, m6- and 2-positions respectively in this order, therefor it is useful as an intermediate for synthesizing targeted polysubstituted 7-deazapurine derivative. SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS

Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

PYRROLOPYRIMIDINE DERIVATIVES AS MPS1/TTK KINASE INHIBITORS

Disclosed herein are novel compounds that are Mps1/TTK inhibitors. Also disclosed are compositions comprising the compounds and methods of using the compounds in treating various diseases.

NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS

Novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.

Synthesis and photophysical properties of oligoarylenes with a pyrrolo[2,3-d]pyrimidine core

The palladium-catalyzed Suzuki-Miyaura reaction of 2,4-dichloropyrrolo[2,3-d]pyrimidine with aryl boronic acids has been studied. Pd(OAc)2/dicyclohexyl(2-biphenyl)phosphine/K3PO4 was found to be an efficient catalyst system to prepare 4-aryl-2-chloro- and 2,4-diarylpyrrolo[2,3-d]pyrimidines. Novel non-linear molecules consisting of a pyrrolo[2,3-d]pyrimidine core and aryl branches have been elucidated as blue light-emitters with fluorescence quantum yields ranging from 4% to 67% in THF solution. The impact of an electron-withdrawing t-BuOCO group attached to the pyrrole ring of pyrrolopyrimidine derivatives on optical properties is discussed.

Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines

A series of pyrazolo[3,4-d]pyrimidine, pyrrolo[2,3-d]pyrimidine and 6-arylpurine adenosine A2A antagonists is described. Many examples were highly selective against the human A1 receptor sub-type and were active in an in vivo model of Parkinson's disease.